Future Directions in Graft Versus Host Disease

EP: 1.Graft versus Host Disease Background

EP: 2.Overview of GVHD Risk Factors

EP: 3.Current GVHD Prophylaxis Strategies

EP: 4.Signs and Symptoms of Acute and Chronic GVHD

EP: 5.Statistics on the Incidence of Chronic GVHD

EP: 6.Identification of Patients at High Risk for GVHD

EP: 7.Assessment of Chronic GVHD Symptoms

EP: 8.The NIH Clinical Scoring of Organ Systems

EP: 9.The Chronic GVHD Treatment Paradigm

EP: 10.Patient Case: A 48-Year-Old Man with Chronic GVHD

EP: 11.Treatment Goals for a Patient With Chronic GVHD

EP: 12.Steroid-Refractory Chronic GVHD Background

EP: 13.Therapy Options for Steroid-Refractory Chronic GVHD

EP: 14.Ibrutinib as Second-Line Therapy for Steroid-Refractory Chronic GVHD

EP: 15.The iNTEGRATE Trial: Ibrutinib With Prednisone as First-Line Therapy for cGVHD

EP: 16.The REACH3 Clinical Trial of Ruxolitinib in Chronic GVHD

EP: 17.Clinical Experience with Ruxolitinib for cGVHD

EP: 18.The ROCKstar Study of Belumosudil in cGVHD

EP: 19.Real-World Experience with Belumosudil

EP: 20.Summary of Axatilimab for cGVHD

EP: 21.Therapy Selection for Patients with Chronic GVHD

EP: 22.Discussion of Long-Term Effects of GVHD Therapy

Now Viewing

EP: 23.Future Directions in Graft Versus Host Disease

Transcript:

Yi-Bin Chen, MD: So, we're reaching the end of our discussion here. I'll just ask a question going forward to each of our panelists here and the question will be, what are you most excited about in chronic graft-versus-host disease in the next 5 years? And it can be anything. So, we'll start with Catherine. Go ahead.

Catherine J. Lee, MD, MS: Compared to the 2 of you, I'm fairly more recent to that field. And so for me, it's really exciting to see these sort of targeted agents coming out and seeing how the biology and us understanding the evolution of the science of graft-vs-host disease, chronic graft-vs-host disease, how it continues to reveal itself, even though there's still quite a lot that's not known, but then bringing this to the clinical care setting and possibly testing combination therapies in the future. To me, this is super exciting.

Yi-Bin Chen, MD: How about you, Colleen?

Colleen Danielson, NP: I think having more options for treatment of GVHD is really exciting. I think the other piece that we touched upon is the idea of biomarkers and being able to predict who's at higher risk for chronic GVHD. So, we can try to prevent this, as we all know, the treatments – a lot of the treatment goals for our moderate or severe GVHD patients is to try to stabilize the disease. And so, if we can try to prevent it or know who's at higher risk is really exciting. And then I think the survivorship world as that's growing in our field, and really addressing patients’ quality of life, their psychosocial needs, all of that that goes into their long-term GVHD management and care is really important and exciting, too.

Yi-Bin Chen, MD: Corey, Catherine said, you've been doing this a long time. So, what would – what are you most excited about in the next 5 years?

Corey S. Cutler, MD, MPH, FRCPC: Well, I think, to me the next big challenge—and I think something we might end up getting across—is finding a way to predict which drug for which patient. And so perhaps even more important than who's going to get chronic GVHD is how can we treat it effectively and early on. And as the armamentarium increases, as we have more and more drugs that are approved, understanding which is the right drug for the right patient is going to become increasingly more important. And there are some efforts to try to match that both clinically and biologically. And I'm hopeful we get there.

Yi-Bin Chen, MD: So, on those sentiments, thank you to our panel, for thoughtful case presentation and informative discussion to our viewing audience. Thank you for joining us for this Targeted Oncology™ Virtual Tumor Board® presentation. We do hope today's discussion was a valuable use of your time and then you acquire practical knowledge that you can use in your clinical practice. Thank you very much.

Transcript is AI-generated and edited for clarity and readability.